XML 50 R38.htm IDEA: XBRL DOCUMENT v3.5.0.2

INTANGIBLE ASSETS, NET (Details Narrative)	3 Months Ended		9 Months Ended
	Sep. 30, 2016 USD ($) Number	Sep. 30, 2015 USD ($)	Sep. 30, 2016 USD ($) Number	Sep. 30, 2015 USD ($)
Amortization expense | $	$ 13,917	$ 8,692	$ 38,560	$ 22,296
Number of issued patents	17		17
Hormone Therapy Drug Candidate Patents - (Pending) [Member]
Useful Life			16 years
Opera Software Patent [Member]
Useful Life			13 years
Number of issued patents	1		1
Approved Hormone Therapy Drug Candidate Patents [Member]
Useful Life			20 years
Utility Patent Progesterone and Estradiol Products [Member]
Number of issued patents	13		13
Utility Patent TX-004HR [Member]
Number of issued patents	2		2
Utility Patent Pipeline Transdermal Patch Technology [Member]
Number of issued patents	1		1

X

- Definition

Number of issued patents.

+ References

No definition available.

+ Details

Name:	txmd_NumberOfIssuedPatents
Namespace Prefix:	txmd_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	instant

X

- Definition

The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=66902209&loc=d3e3602-108585

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 350
-SubTopic 30
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-URI http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275

+ Details

Name:	us-gaap_AmortizationOfIntangibleAssets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

No definition available.

+ Details

Name:	us-gaap_FiniteLivedIntangibleAssetUsefulLife
Namespace Prefix:	us-gaap_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=txmd_HormoneTherapyDrugCandidatePatentsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_ApprovedHormoneTherapyDrugCandidatePatentsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents1Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_PatentsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=txmd_Patents2Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: